title: Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.
abstract: Alemtuzumab is a humanized monoclonal antibody that recognizes the CD52 antigen expressed on malignant and normal B lymphocytes. It has come to be used therapeutically in B-cell malignancies and, in addition, it shows interesting activity also in T-cell lymphomas. Published literature and abstract proceedings were scanned, and a systematic review of phase II studies administering alemtuzumab in patients with T-cell lymphomas was performed. Alemtuzumab is an effective alternative option for patients with peripheral T-cell lymphomas and cutaneous T-cell lymphomas. Alemtuzumab may belong to the current standard of care for nodal and cutaneous T-cell lymphomas.
authors: University of Bologna, Bologna, Italy. pierluigi.zinzani@unibo.it
authors: Pier Luigi
authors: PL
authors: Zinzani
authors: Paolo
authors: P
authors: Corradini
authors: Andrea
authors: A
authors: Gallamini
authors: Alberto
authors: A
authors: Grossi
authors: Mario
authors: M
authors: Lazzarino
authors: Monia
authors: M
authors: Marchetti
authors: Maurizio
authors: M
authors: Martelli
authors: Giuseppe
authors: G
authors: Rossi
authors: Umberto
authors: U
authors: Vitolo
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab